Why Kestra Medical Technologies, Ltd.’s (KMTS) Stock Is Up 6.88%
As of Monday, October 19, Kestra Medical Technologies, Ltd.’s KMTS share price has surged by 6.88%, which has investors questioning if this is right time to sell.Michael Rose
Stock Evaluator: Kestra Medical Technologies, Ltd. (KMTS)
Kestra Medical Technologies, Ltd. KMTS
$29.99
0.57
1.94%
October 27, 2026 4:00:00 PM
EST
Volume: 514,267
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Health Care Equipment & Supplies |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Kestra Medical Technologies, Ltd. operates as a wearable medical device and digital healthcare company. It focuses on transforming patient outcomes in cardiovascular disease through connected monitoring, therapeutic intervention, and data-driven clinical insights. The company also develops and commercializes Cardiac Recovery System platform, an integrated cardiac recovery ecosystem designed to support patients at elevated risk of sudden cardiac arrest (SCA) during vulnerable periods of recovery. Its platform provides ASSURE Wearable Cardioverter Defibrillator (WCD), which continuously monitors patient heart rhythms and automatically delivers defibrillation therapy when life-threatening ventricular arrhythmias are detected; digital patient engagement and clinical workflow solutions designed to improve patient adherence, support care coordination, and provide actionable clinical insights throughout the recovery process; and integrated platform generates continuous cardiac rhythm data and clinically actionable insights. Kestra Medical Technologies, Ltd. was founded in 2014 and is based in Kirkland, Washington.
Commentary & Analysis
Why Kestra Medical Technologies, Ltd.’s (KMTS) Stock Is Up 5.18%
As of Thursday, October 15, Kestra Medical Technologies, Ltd.’s KMTS share price has surged by 5.18%, which has investors questioning if this is right time to sell.Jenna Brashear
What You Need to Know About Kestra Medical Technologies, Ltd.'s Q2 Earnings
Kestra Medical Technologies, Ltd.'s fiscal Q2 earnings report was released on Monday, September 14. Let's dive in to see if (KMTS) missed or beat analyst's expectations.Jenna Brashear
Is Kestra Medical Technologies, Ltd. (KMTS) Overvalued?
We dive into why Kestra Medical Technologies, Ltd. (KMTS) could be considered overvalued on 2026-08-07, based on AAII’s Value Score and Grade.Rosalio Madrigal
Why Kestra Medical Technologies, Ltd.’s (KMTS) Stock Is Up 6.21%
As of Monday, August 10, Kestra Medical Technologies, Ltd.’s KMTS share price has surged by 6.21%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Financial Summary
| Share Statistics | KMTS | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,752.3 | $403.5 | 53% |
|
| Shares Out (Mil) | 58.6 | 40.7 | 51% |
|
| Institutional Ownership | 98.2% | 83.3% | 77% |
|
| Float (Mil) | 33.7 | 34.5 | 38% |
|
| Beta | na | 0.85 | na |
|
| Avg Daily Volume (000s) | 462 | 272 | 57% |
|
| Price Change (52-week) |
14.5% | 63.7% | 65% |
|
| Growth | KMTS | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 11.8% | na |
|
| Net Income (5yr) | (34.9%) | (5.5%) | 11% |
|
| EPS (5yr) | 61.3% | 10.7% | 96 |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | 1.2% | (15.6%) | 65% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 2 | 2 | 2 | |
| Current EPS | ($0.605) | ($2.450) | ($2.055) | |
| Month Ago EPS | ($0.605) | ($2.450) | ($2.055) | |
| # Rev Up | 0 | 1 | 1 | |
| # Rev Down | 1 | 3 | 2 | |
| Three Months Ago EPS | ($0.615) | ($2.305) | ($2.020) | |
| Year/Year Chg | (19.7%) | 0.9% | (34.8%) | |
| Financials | KMTS | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $107 | $141 | 27% |
|
| Net Income (TTM) (Mil) | ($150) | ($9) | 9% |
|
| EPS (TTM) | ($2.676) | ($0.400) | 12% |
|
| Operating Cash Flow (TTM) (Mil) | ($88) | ($2) | 7% |
|
| Net Cash Flow (TTM) (Mil) | ($133) | $1 | 13% |
|
| Long-Term Debt (Q1) (Mil) | $76 | $27 | 42% |
|
| Enterprise Value (Q1) (Mil) | $1,312 | $418 | 44% |
|
| Valuation | KMTS | Industry Median |
Percentile (All Stocks) |
|
| P/B | 7.85 | 2.50 | 88% |
|
| P/E | na | 27.4 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.5 | na |
|
| Ratios | KMTS | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 53.9% | 59.3% | 66% |
|
| Net Margin | (140.4%) | (6.9%) | 6% |
|
| ROA | (48.8%) | (12.2%) | 12% |
|
| ROE | (73.7%) | (10.7%) | 12% |
|
| Liabilities to Assets | 36.0% | 47.2% | 27% |
|
| F-Score | 2 | 4 | 7% |
|
Kestra Medical Technologies, Ltd. did not pass any screens on 10/26/2026.
